Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PCVX
PCVX logo

PCVX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Vaxcyte Inc (PCVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
51.440
1 Day change
1.52%
52 Week Range
65.000
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, Vaxcyte Inc (PCVX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive momentum with recent price increases, strong congressional buying activity, and favorable technical indicators. While there are no immediate AI or SwingMax trading signals, the overall sentiment and data support a long-term investment decision.

Technical Analysis

The MACD histogram is positive at 0.734 and expanding, indicating bullish momentum. The RSI is at 71.785, which is in the neutral zone but leaning towards overbought territory. Moving averages are converging, suggesting a potential breakout. Key resistance levels are at 52.109 and 54.039, with support at 45.859 and 43.929. The stock closed above the first resistance level, signaling strength.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The high open interest put-call ratio suggests bearish sentiment in the options market, but the low option volume put-call ratio indicates that recent trading activity is more bullish. Implied volatility is relatively low, with an IV percentile of 14.29 and IV rank of 6.26, suggesting reduced risk of significant price swings.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
7

Positive Catalysts

  • Congressional trading data shows two significant purchase transactions in the last 90 days, indicating confidence from influential figures.

  • The stock has shown consistent price increases in pre-market, regular market, and post-market trading.

  • Technical indicators like MACD and moving averages suggest bullish momentum.

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts to further support the stock.

  • Options data shows a high open interest put-call ratio, indicating some bearish sentiment among options traders.

  • Stock trend analysis suggests limited short-term upside potential, with a 40% chance of minor declines in the next day or month.

Financial Performance

No financial data available for analysis due to an error in the provided dataset.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data provided for evaluation.

Wall Street analysts forecast PCVX stock price to rise
6 Analyst Rating
Wall Street analysts forecast PCVX stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 50.670
sliders
Low
50
Averages
104.8
High
163
Current: 50.670
sliders
Low
50
Averages
104.8
High
163
TD Cowen
Tara Bancroft
Buy
upgrade
$50 -> $75
AI Analysis
2026-02-25
Reason
TD Cowen
Tara Bancroft
Price Target
$50 -> $75
AI Analysis
2026-02-25
upgrade
Buy
Reason
TD Cowen analyst Tara Bancroft raised the firm's price target on Vaxcyte to $75 from $50 and keeps a Buy rating on the shares. The firm said Vaxcyte enters 2026 with a largely de-risked path for VAX-31, supported by differentiated Phase II data and a comprehensive Phase III OPUS program targeting BLA filing in 2027.
Goldman Sachs
Neutral
maintain
$38 -> $67
2026-02-25
Reason
Goldman Sachs
Price Target
$38 -> $67
2026-02-25
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Vaxcyte to $67 from $38 and keeps a Neutral rating on the shares. Since coverage initiation, shares have risen steadily due to clinical progress on VAX-31, a slower-than-expected competitive landscape, and stable policy around the 4-dose infant schedule, contributing to year-to-date outperformance, the analyst tells investors in a research note. Upcoming VAX-31 Phase 3 adult data, Phase 2 pediatric readouts, and competitive developments viewed as key de-risking catalysts, the firm adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PCVX
Unlock Now

People Also Watch